Clinical Trial Update: An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. [Phase 2]

View source ↗

Summary

Phase 2 trial comparing three doses of BEA 2180 BR to tiotropium and placebo in COPD; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BEA 2180 BR
• tiotropium (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2021-08-24